%0 Journal Article
%T Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer ¨C a phase I study
%A U Ganswindt
%A W Budach
%A V Jendrossek
%A G Becker
%A M Bamberg
%A C Belka
%J Radiation Oncology
%D 2006
%I BioMed Central
%R 10.1186/1748-717x-1-9
%X In order to rule out any increases of more than 20% incidence for a given side effect level 22 patients were included in the trial. Celecoxib was given 400 mg twice daily with onset of the radiation treatment. Risk adapted radiation doses were between 70 and 74 Gy standard fractionation. RTOG based gastrointestinal (GI) and genitourinary (GU) acute toxicity scoring was performed weekly during radiation therapy, at six weeks after therapy and three month after completing radiation treatment.Generally no major increase in the level and incidence of side effects potentially caused by the combined treatment was observed. In two cases a generalised skin rash occurred which immediately resolved upon discontinuation of the drug. No grade 3 and 4 toxicity was seen. Maximal GI toxicity grade 1 and 2 was observed in 85% and 10%, respectively. In terms of GU toxicity 80 % of the patients experienced a grade 1 toxicity and 10 % had grade 2 symptoms.The combination of irradiation to the prostate with concurrent high dose celecoxib was not associated with an increased level of side effects.Prostate cancer is the most common malignant tumour in men. At present, approximately 200.000 new diseases are diagnosed per year in the USA leading to the death of more than 30.000 patients. Due to the increased use of PSA screening the number of patients diagnosed in localised disease is rising strongly. Radical prostatectomy, percutaneous radiotherapy and interstitial radiation methods are available for curative treatment of localised stages. Due to a lack of randomised studies, the optimal treatment is still unclear. Based on the available data, however it seems likely that all given methods are more or less equivalent in terms of tumour control. Side effects in the rectum predominate with percutaneous radiotherapy, while mainly impotence and incontinence are seen after prostatectomy [1].Nevertheless, a crucial problem is still unsolved. The long natural history of prostate cancer makes it
%U http://www.ro-journal.com/content/1/1/9